Cystitis, Interstitial Clinical Trial
Official title:
A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a difficult disease to both diagnose and treat. It is defined as an unpleasant sensation (pain, pressure, or discomfort) perceived to be related to the urinary bladder and associated with lower urinary tract symptoms for at least 6 weeks duration, in the absence of infection or other identifiable causes. Pain is the universal symptom, but many also experience symptoms of overactive bladder, possibly directly related to the mechanism of pain. Treating pain may influence the symptom of urgency, if the urge arises from a need to alleviate pain. In some patients whose pain improves with treatment, troubling overactive bladder symptoms still remain. Beta-3 adrenergic agonists have been found to decrease signaling of C-fibers in animal models. So, the investigators hypothesize that mirabegron, which is FDA-approved for treatment of overactive bladder, would also improve symptoms in patients with BPS/IC. As a selective beta-3 agonist, mirabegron acts on the beta-3 receptors found in the bladder which mediate relaxation of the detrusor muscle. It has been shown to significantly decrease the number or micturition episodes, urgency episodes, and increased mean volume of urine voided per micturition. It also has a favorable tolerability profile.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02868775 -
A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
| Completed |
NCT00672087 -
Diagnostic Challenges in IC (and Male CPPS)
|
||
| Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
| Completed |
NCT00775281 -
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
|
N/A | |
| Terminated |
NCT00380783 -
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
|
Phase 2 | |
| Completed |
NCT05260112 -
Smartphone-based Self-care Education Program for Women With Interstitial Cystitis: Educational Remote IC Aide
|
N/A | |
| Completed |
NCT05752344 -
Interstitial Cystitis: Monitoring of the Psychic State and Counseling Intervention in the COVID-19 Era
|
||
| Completed |
NCT01613586 -
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
|
Phase 2 | |
| Completed |
NCT02411110 -
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
| Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
| Completed |
NCT00248664 -
Events Preceding Interstitial Cystitis (EPIC)
|
N/A | |
| Completed |
NCT00601484 -
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
|
Phase 2 | |
| Completed |
NCT02214550 -
Chronic Pain Risk Associated With Menstrual Period Pain
|
Phase 4 | |
| Completed |
NCT04275297 -
Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
| Terminated |
NCT00999518 -
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
|
Phase 2 | |
| Completed |
NCT00675298 -
Linkage Analysis in Interstitial Cystitis
|
N/A | |
| Terminated |
NCT02781103 -
Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain
|
N/A | |
| Recruiting |
NCT01074567 -
DMSO Efficacy in IC/PBS Patients During and After Treatment
|
N/A | |
| Completed |
NCT02497976 -
Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
|
Phase 3 | |
| Withdrawn |
NCT00275379 -
Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis
|
N/A |